ERBB2 and breast carcinoma: On the other hand, Mahmoud et al. did not find a dominant role of FoxP3+ cells in breast cancer prognosis in multivariate analyses [22], while Ladoire et al. found FoxP3 expression to be associated with better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy [23].